This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
San Diego-based Arcturus Therapeutics , a developer of mRNA-based treatments for disease, has signed a deal to receive up to $3M in funding from the Cystic Fibrosis Foundation Therapeutics, a nonprofit which supports drug discovery and development. READ MORE>>.
San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. Names of those capital sources were not announced. READ MORE>>.
Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. SanDisk said it would pay $327M in cash, plus equity-based incentives for Pliant, a developer of enterprise solid state disk drives (SSDs).
San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech' and Canada.
Simi Valley-based unmanned aerial vehicle maker Aerovironment says it is acquiring Arcturus UAV, a developer of unmanned aircraft used by the military, in a deal worth $405M in cash and stock. AeroVironment said it would pay $355M in cash and $50M in stock for Arcturus, which is based in Petaluma, Claifornia.
Messenger RNA drug developerArcturus Therapeutics is ready to kick off its first-ever human trials this year, beginning clinical evaluation of its lead drug candidate and testing a vaccine designed to target the novel coronavirus. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
San Diego-based RNA therapeutics developerArcturus Therapeutics announced this morning that it is in a strategic collaboration deal, with Johnson & Johnson Innovation. Plus, Janssen will assume responsibility for development and commercialization costs associated with the new program. READ MORE>>.
San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds.
Los Angeles-based Arcturus, a developer of 3D video editing tools, said Wednesday afternoon that it has raised $11M in a Series A funding round. The funding was led by Cloudtree Ventures, and also included Autodesk and Epic Games. The startup is led by CEO Kamal Mistry.
Monrovia, California-based Prolacta Bioscience , the venture backed firm developing human milk fortifiers for premature infants, announced this morning that it will be donating funds to the Susan G. Komen for the Cure as part of its milk donation program.
Things have been moving quickly in recent weeks for the San Diego RNA drug developerArcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies.
San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. Arcturus says its technology can be used to make.
Prolacta has been developing processes which process human milk, and convert that into human milk fortifier which helps prevent medical issues often encountered by feeding premature babies with cow-based fortifiers. According to Prolacta, the National Milk Bank will recruit potential breast milk donors for Prolacta. READ MORE>>.
In the five years since it was founded, San Diego-based Arcturus Therapeutics (NASDAQ: ARCT ) says it has built a versatile platform for developing a variety of RNA-based medicines. Dueling lawsuits between the ousted CEO and the board could consume. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Arcturus Therapeutics (NASDAQ: ARCT ) said today it has fired co-founder and CEO Joseph E. Payne (on the right in above photo), and named Mark Herber, vice president of business development and alliance management, as interim president. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
The San Diego RNA drug developerArcturus Therapeutics (NASDAQ: ARCT ) named four new board members Tuesday, after the four directors who fired founding CEO Joseph Payne resigned as part of a settlement agreement that was approved Monday by an Israeli court. No financial terms were disclosed.
The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing key financial reporting deadlines, and possibly even losing its stock listing. The San Diego drug developer said late Monday that the typically routine step of ratifying the company’s auditor failed a shareholder vote.
The San Diego RNA drug developerArcturus Therapeutics (NASDAQ: ARCT ) on Thursday reinstated fired CEO Joseph Payne and named ResMed (NYSE: RMD ) founder Peter Farrell as chairman of the company’s new board of directors. He co-founded Arcturus and is the company’s largest shareholder, with a 13.7 percent stake.
The board that fired Arcturus Therapeutics co-founder and CEO Joseph E. Payne earlier this year unleashed a new broadside this week in the ongoing battle for control of the San Diego-based RNA drug developer. Payne, who. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Most recently, XIFIN said, Zaniboni was CFO of AviaraDx, while Taylor served as vice president of marketing and corporate development for Acclerys Inc. Zaniboni was also CFO for Arcturus Bioscience and Sequenom, XIFIN noted, adding that Taylor worked at IBM as a strategy executive prior to Acclerys.
Long Beach-based Digital Performance, which develops technology for online sales efforts in the after market automotive parts sector, is announcing Monday that it has raised $3.2M The round was led by Rincon Venture Partners, and also included Arcturus Capital and Momentum Venture Management. in a Series A funding round.
Santa Monica-based Zag, a venture-backed developer of online car buying software, said this morning that it has made. Zag said it has promoted Bernie Brenner to Executive Vice President in charge of the firm's consumer initiatives, named David Pributsky as VP of Partner development. a number of hires and a promotion. READ MORE>>
Santa Monica-based Zag , which has developed an automobile configuration and buying service for affinity organizations like credit unions and automobile organizations, has a funding round of undisclosed size. The spokesperson for Zag said that the firm is "not quite ready to make that announcement" and would not releas details until later.
Santa Monica-based Zag , which has developed an automobile configuration and buying service for affinity organizations like credit unions and automobile organizations, has raised around $32.4M in a funding round. A spokesperson for Zag told socalTECH that a round had closed, but would not confirm the investors or details of the round.
Santa Monica-based Zag, which is developing software for auto buying programs, has signed on another AAA group as a customer. Zag has developed a software product which allows users to fully configure and price cars for car buying programs and affinity groups; the firm's software is already being used by a number of other AAA clubs.
Alnylam had sold the drug’s development and commercialization rights seven years ago. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol. Now in the hands of Novartis (NYSE: NVS ), the potential blockbuster seller awaits an FDA decision.
As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat these “superbugs.” San Diego’s Forge Therapeutics is among those targeting gram-negative bacteria, a type of bacteria that has a protective outer membrane that makes it especially resistant to drugs.
A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. But the results, touted as positive, left more questions than answers.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content